Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates

Group 1 - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has shown strong performance, with a 6.81% increase in stock price, closing at $4.86, as investors anticipate business updates from upcoming conferences [1] - The company's president and CEO, Najat Khan, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference and the 28th Annual Needham Growth Conference [2] - Investors are particularly interested in updated guidance regarding earnings performance for 2025, pipeline updates, and the outlook for 2026 [3] Group 2 - JPMorgan has upgraded Recursion Pharmaceuticals to "overweight" from "neutral" and raised its price target from $10 to $11, indicating increased confidence in the stock [3] - The upgrade follows positive results from the clinical trial of REC-4881, a therapy candidate for Familial Adenomatous Polyposis, which is projected to generate $1 billion in sales in the U.S. [4]